Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sunesis

Sunesis?uq=UG6efJS6
1998 FOUNDED
PUBLIC STATUS
31-40 EMPLOYEES
SNSS STOCK SYMBOL
$1.84 SHARE PRICE (As of Thursday Closing)
Description

Developer of biopharmaceutical drugs designed to develop and commercialize new oncology therapeutics. The company's biopharmaceutical drug QINPREZO is the lead product candidate for the potential treatment of acute myeloid leukemia which contains Vosaroxin, an anticancer quinolone derivative, a class of compounds that has not been used previously for the treatment of cancer, enabling physicians to treat solid and hematologic cancers.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Sunesis’s full profile, request a free trial.

Sunesis Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.84 - $7.36 $70.8M $1.96 -$0.99 115K 36.1M

Sunesis Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 76,730 137,615 82,144 54,901
Revenue 237 669 2,536 3,061
EBITDA (29,750) (34,053) (36,291) (35,710)
Net Income (30,895) (35,458) (38,023) (36,676)
Total Assets 22,021 34,334 43,234 47,002
Total Debt 7,300 7,204 14,435 7,834
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sunesis Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sunesis‘s full profile, request access.

Request full access to PitchBook

Sunesis Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sunesis‘s full profile, request access.

Request full access to PitchBook

Sunesis Executive Team (15)

Name Title Board
Seat
Contact
Info
Dayton Misfeldt Interim Chief Executive Officer & Board Member
William Quinn Chief Financial Officer & Senior Vice President, Finance and Corporate Development
Judith Fox Ph.D Chief Scientific Officer
Deborah Thomas Ph.D Senior Vice President, Regulatory Affairs, Quality Assurance and Nonclinical Development
Jennifer Smith Ph.D Vice President, Biometrics

6 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Sunesis Board Members (11)

Name Representing Role Since Contact
Info
David Stump MD Self Board Member 000 0000
Dayton Misfeldt Self Interim Chief Executive Officer & Board Member 000 0000
Geoffrey Parker Self Board Member 000 0000
Homer Pearce Ph.D Self Board Member 000 0000
Matthew Fust Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »